Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494150 · ClinicalTrials.gov registry record · Phase 2
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
A Phase 2 study of Low Grade Ovarian Serous Adenocarcinoma, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT06494150 is a Phase 2 study of Low Grade Ovarian Serous Adenocarcinoma that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 37 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06494150, a Phase 2 study of Low Grade Ovarian Serous Adenocarcinoma, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).
Conditions Studied
Interventions
- DRUG nab-Sirolimus
- DRUG Fulvestrant
Study Locations (1)
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06494150
The ClinicalTrials.gov registry entry for NCT06494150 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low Grade Ovarian Serous Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which nab-Sirolimus is the first listed.
NCT06494150 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06494150 about?
NCT06494150 is a clinical study titled "Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)". This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).
What is the current status of trial NCT06494150?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2024-12-26. Estimated completion is 2029-09.
What conditions does trial NCT06494150 study?
This clinical trial studies the following conditions: Low Grade Ovarian Serous Adenocarcinoma.
What interventions are being tested in trial NCT06494150?
The interventions under investigation include: nab-Sirolimus (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT06494150?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494150 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Ovarian Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.